SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001140361-23-050866
Filing Date
2023-11-01
Accepted
2023-11-01 16:58:41
Documents
1
Group Members
GNI USA, INC.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A ny20009756x11_sc13da.htm SC 13D/A 64005
  Complete submission text file 0001140361-23-050866.txt   65700
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 250 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 250 SAN DIEGO CA 92130 650-266-8674
GYRE THERAPEUTICS, INC. (Subject) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-82442 | Film No.: 231369037
SIC: 2834 Pharmaceutical Preparations

Mailing Address NIHONBASHI-HONCHO YS BLDG 3F 2-2-2 NIHONBASHI-HONCHO, CHUO-KU TOKYO M0 103-0023
Business Address NIHONBASHI-HONCHO YS BLDG 3F 2-2-2 NIHONBASHI-HONCHO, CHUO-KU TOKYO M0 103-0023 81-3-6214-3600
GNI Group Ltd. (Filed by) CIK: 0001958461 (see all company filings)

IRS No.: 000000000
Type: SC 13D/A